- Given the present cash balance and upcoming partner payments we don’t think investors have to worry about cash anytime soon.
- The question will be, how fast can the company ramp sales to grow into its $1.4B valuation.
- We think signing up 100K US patients, not even counting foreign royalty income, would do the trick, which seems a very low bar to us.
Esperion Has A Low Bar To Climb To Warrant Its Present Valuation
May 24th, 2020 · No Comments